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Characterization of rSEA-EGF and In Vitro
Evaluation of its Antitumor Activity
Against Nasopharyngeal Cancer
Xueting Liu, PhD1, Liping Zeng, BS1, Zhongqiu Zhao, PhD2,3,
Yang Xie, MS1, Shan Wang, PhD1, Junyan Zhang, PhD1, Ying He, MS1,
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Abstract
Staphylococcal enterotoxin A is well known as a superantigen and able to be used for cancer immunotherapy. In this study,
recombinant Staphylococcal enterotoxin A was genetically conjugated to epidermal growth factor to produce a chimeric protein
recombinant Staphylococcal enterotoxin A–epidermal growth factor expressed in Escherichia coli. The recombinant Staphylococcal
enterotoxin A–epidermal growth factor protein was purified using Strep-Tactin affinity chromatography and Endotoxin Removal
Resin and identified by sodium dodecyl sulfate-polyacrylamide gel electropheresis and liquid chromatography-tandem mass
spectrometry analysis. Furthermore, in vitro experiments showed purified recombinant Staphylococcal enterotoxin A–epidermal
growth factor could successfully bind to the human nasopharyngeal carcinoma cell line CNE2, significantly promote the pro-
liferation of human peripheral blood mononuclear cells, and enhance the secretion of several cytokines that have broad antitumor
activities, such as interferon-g, tumor necrosis factor-a, and interleukin-2 . Importantly, recombinant Staphylococcal enterotoxin
A–epidermal growth factor significantly inhibited proliferation of CNE2 cells and promoted apoptosis in CNE2 cells when
cocultured with peripheral blood mononuclear cells. Finally, both the binding of recombinant Staphylococcal enterotoxin A–
epidermal growth factor and the toxicity of recombinant Staphylococcal enterotoxin A–epidermal growth factor-activated per-
ipheral blood mononuclear cells were demonstrated as specific and only effective on high epidermal growth factor receptor-
expressing cell lines. In all, our work suggests that recombinant Staphylococcal enterotoxin A–epidermal growth factor serves as a
promising novel immunotherapeutic agent. More in vivo and in vitro studies are needed to verify its antitumor potency, as well as
investigate the underlying mechanisms in cancer immunotherapy.
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therapeutics, nasopharyngeal cancer.
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Introduction
Over the past half century, the clinical management of cancer
has relied on 3 conventional anticancer therapies—surgery,
radiation therapy, and chemotherapy—but, unfortunately, cur-
rent clinicians and scientists are still struggling to cope with the
multiple challenges such as lack of cancer epigenetic profiling
and drug specificity, metastasis, and drug resistance.1-3 Over
the past 2 decades, immunotherapy, also called as biologic
therapy, has been considered as a new and exciting field of
cancer treatment from basic scientific research to clinical
applications. Immunotherapies with a variety of approaches,
including oncolytic viruses, cancer vaccines, checkpoint inhi-
bitors, chimeric antigen receptor (CAR) T cells, natural killer
cells, and genetically modified dendritic cells, and so on,
either stimulate the responses of the innate immune system
(“active” therapies) or counteract signals produced by cancer
cells that suppress or avoid immune activities (“passive”
therapies).2-4 Currently, there are quite a few immune check-
point inhibitors that have been approved by the Food and
Drug Administration.2-6 In all, at least 2 immunotherapeutic
approaches, checkpoint inhibition and cellular therapy with
CAR T cells, have already shown promising antitumor effects
either when used alone or when combined with existing con-
ventional therapies.2-6
Cancer vaccines have been used to both treat and prevent
cancer by targeting the immune system.2,3,7 Similar to classic
vaccines, most therapeutic cancer vaccines are also made using
protein or peptide antigens. Staphylococcal enterotoxins (SEs)
are powerful peptide antigens produced by Staphylococcus
aureus and there are more than 20 distinct SEs which share a
number of genetic, biochemical, and functional characteris-
tics.8 Staphylococcal enterotoxin A and SEB are 2 SEs that
have been well characterized. They nonspecifically cross-link
the major histocompatibility complex class II molecules on
antigen-presenting cells and specific V regions of T-cell recep-
tors, thus resulting in hyperactivation of both T lymphocytes
and monocytes/macrophages.8 These activated host cells pro-
duce excessive amounts of cytokines and chemokines, that is,
tumor necrosis factor a (TNF-a), interleukin 1 (IL-1), IL-2,
interferon g (IFN-g), and macrophage chemoattractant protein
1 (or CCL2), and so on, that are involved in the pathogenesis of
a number of inflammatory and/or autoimmune disorders, and
even cancer.8-10
In the past, both SEA and SEB were fused to either Fab
fragments of tumor reactive monoclonal antibodies (mAbs) or
to ligands that bind to receptors expressed or overexpressed
on the target cells and were named “ligand-targeted therapeu-
tics (LTTs).”2,3 These LTTs have been used in animal studies
and effectively inhibited breast cancer,11-13 bladder cancer,14
melanoma,12,13,15 and so on. Recent studies have defended
that the use of SEs in immunotherapy is not “outdated,” but
actually a great treatment option for cancer therapy as long as
we learn more about efficient modes of SE engineering and
administration and the dynamics of the SE-induced host anti-
tumor immune response.7-9 Nasopharyngeal cancer is
believed to be Epstein-Barr virus associated and rare in the
west but endemic in the east (ie, in Southern China, the annual
incidence is over 30 per 100 000 persons).16,17 Although naso-
pharyngeal cancer is highly sensitive to radiotherapy and che-
motherapy in its early stage, outcomes are poor in its
advanced stage and better treatments are urgently needed.16-
18 Up to now, there hasn’t been any report regarding introdu-
cing SEs or SE-induced LTTs in treating nasopharyngeal
cancer.
Epidermal growth factor (EGF) is the natural ligand that
binds to the EGF receptor (EGFR) and activates more than
200 downstream signal molecules to initiate or modulate var-
ious intracellular processes.18-21 Most nasopharyngeal cancer
cell lines and patients overexpress EGFR, which was thus
proposed as a new target for cancer treatment.18-21 Therefore,
in this study, we produced a fusion protein from SEA geneti-
cally conjugated to EGF forming a chimeric construct
(referred to as recombinant SEA-EGF). The fusion protein
was expressed in Escherichia coli. The purified fusion protein
sequence was then identified by liquid chromatography-tan-
dem mass spectrometry (LC-MS/MS) analysis, its ability to
bind to the cancer cells was determined, and its in vitro anti-
tumor effect was examined. To our knowledge, this is the first




The E. coli strain JM-109 (Promega) was used for plasmid
proliferation and cloning. The E. coli strain Rosetta-gami 2
(Novagen) was used as a host for the production of recombi-
nant proteins. Human nasopharyngeal carcinoma cell line
CNE2 and human embryonic kidney cell line (HEK 293T)
were purchased from the American Type Culture Collection
(ATCC). Plasmid pET-44a was purchased from Promega. All
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primers used in this study were synthesized by Biosune Biol-
ogy and Technology Company (Shanghai, China). NdeI and
XhoI restriction endonucleases, T4 DNA ligase, and PrimeS-
TAR HS DNA polymerase were purchased from Takara Bio-
technology (Dalian, China). Human IL-2, IFN-g, and TNF-a
enzyme linked immunosorbent assay (ELISA) kits were pur-
chased from R&D Systems (Minneapolis, Minnesota, USA). b-
tubulin rabbit mAb and EGFR rabbit mAb were purchased
from Cell Signaling Technology (Danvers, Massachusetts,
USA). Strep-Tag II mAb was purchased fromMerck (Billerica,
Massachusetts, USA). (3-(4,5-dimethylthiazol-2-yl)-5-(3-car-
boxy-methoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium inner
salt) (MTS) reagent for cell proliferation assay was purchased
from Promega (Madison, Wisconsin, USA). Annexin V-
conjugated Alexa Fluor 488 (Alexa488) Apoptosis Detection
Kit was purchased from BD Pharmingen (San Diego, Califor-
nia, USA).
Staphylococcal Enterotoxin A–EGF Gene Amplification
and Plasmid Construction
The chimeric gene was constructed according to our previous
work.22 The SEA gene was amplified from genomic DNA of
S aureus strain ATCC-13565 using primers F1 and R1 (F1: 50-
AGCGAGAAAAGCGAAGAAAT-30; R1: 50-ACTTGTATA-
TAAATATATAT-30). Epidermal growth factor gene was
amplified from complementary DNA (cDNA) of human
parotid gland using primers F2 and R2 (F2: 50-AATAGT-
GACTCTGAATGTCCCCTGTC-30; R2: 50-GCGCAGTTCC-
CACCA -CTTCA -30). To fuse EGF to the C terminal of
SEA, primers R3 and F3 were annealed and extended by splice
overlap extension polymerase chain reaction (PCR) using R4
and F4 (R3: GGACATTCAGAGTCACTATTACTTGTATA-
TAAATATATAT; F3: ATATATATTTATATACAAGTAA-
TAGTGACTCTGAATGTCC). The resultant products were
SEA-EGF. Polymerase chain reaction was carried out to add the
NdeI restriction site, XhoI restriction site, and Strep-tag II for
purification using the F4 and R4 (F4: 50- GGAATTCCATAT-
GAGCGAGAAAAGCGAAGAAAT-30, with NdeI site
underlined; R4: 50-CCGCTCGAGTTATTATTTTTCGAACT -
GCGGGTGGCTCCAGCGCAGTTCCCACCACTTCA-30,
with XhoI site underlined and Strep-Tag II sequence in bold ita-
lic). The digested amplified products were inserted into the NdeI
and XhoI sites of the pET44a vector and transformed into E coli
strain JM109. Cloneswere proliferated and harvested for plasmid
extraction. The positive clones were identified by double diges-
tion, colony PCR, and sequencing analysis. Subsequently, the
pET44a-SEA-EGF plasmid was transformed into E. coli strain
Rosetta-gami 2 for protein expression.
Expression of Recombinant SEA-EGF (rSEA-EGF)
in E. coli
The cultures were grown at 37C until the OD600 (OD absor-
bance-600nm) reached 0.6 to 0.8, followed by the induction of
protein expression with 0.5 mmol/L Isopropyl b-D-1-
thiogalactopyranoside (IPTG) for 4 to 5 hours at 37C. The
inducible expression of rSEA-EGF was analyzed by sodium
dodecyl sulfate polyacrylamide gel electrophoresis (SDS-
PAGE) and verified by Western blotting. Afterward, the cell
pellets were resuspended in lysis buffer (25 mmol/L phos-
phate buffer, 150 mmol/L NaCl, 2 mmol/L EDTA, and 10%
glycerol; pH 7.5) and lysed by sonication. Inclusion bodies
were recovered by centrifugation (6000 rpm, 30 minutes,
4C), washed twice in the wash buffer (2% Triton X-100,
50 mmol/L Tris, and 1 mmol/L EDTA; pH 7.5), and dissolved
in a denaturation solution (6 mol/L guanidine hydrochloride,
10 mmol/L dithiothreitol, 100 mmol/L Tris, and 2 mmol/L
EDTA; pH 8.0).
Refolding and Purification of rSEA-EGF
To obtain the renatured rSEA protein, the denatured inclusion
bodies (final concentration 0.5 mg/mL) were refolded by
dialysis using the renaturation solution (150 mmol/L NaCl,
50 mmol/L Tris, 1 mmol/L EDTA, 1 mmol/L cysteine,
3 mmol/L Glutathione disulfide (GSSG), 3 mmol/L Glu-
tathione (GSH), 0.2% L-arginine and 10% glycerol; pH 8.0).
The renatured rSEA-EGF protein was purified using Strep-
Tactin affinity chromatography (GE Healthcare, Pittsburgh,
Pennsylvania, USA) following dialyzed against binding buf-
fer (150 mmol/L NaCl, 50 mmol/L Tris, 1 mmol/L EDTA; pH
8.0). The purity of rSEA-EGF was analyzed by SDS-PAGE.
To remove any contaminating LPS (Lipopolysaccharide),
rSEA-EGF protein was purified by high-capacity endotoxin
removal resin (Thermo Fisher Scientific, Waltham, Massa-
chusetts, USA). The LPS content was analyzed by the tachy-
pleus amebocyte lysate (TAL) method. Samples that
contained less than 0.5 EU/ mg LPS were deemed to be suit-
able for use in the following assays.
Liquid Chromatography-tandem Mass
Spectrometry Analysis
Liquid Chromatography-tandem Mass Spectrometry analysis
was conducted according to the reference by Guan et al23 with
some modification. Recombinant SEA-EGF was digested by
trypsin at a work ratio of 1:10 (enzyme to protein) at 37C for 4
hours. Next, digested peptides were separated on an Easy-spray
column (15 cm  75 mm ID, 3-mm C18 particles) by using the
EASY-nLC system (Thermo Fisher Scientific, Waltham, Mas-
sachusetts, USA) and were then eluted with 0.1% formic acid
solution in a linear gradient (0%-90%) of methanol at the flow
rate of 300 nL/min for 20 minutes. Finally, a Q Exactive mass
spectrometer (Thermo Fisher Scientific, Waltham, Massachu-
setts, USA) with a resolution of 60 000 at m/z 350 to 1800 was
used to acquire high-resolution spectra. All the measured MS/
MS (tandem mass spectrometry) results in an mascot generic
format (MGF) file were studied with the Analyst software 1.3.2
Mascot script. Using the Mascot MS/MS ion search engine
(Matrix Science, Boston, Massachusetts), the unknown pep-
tides were identified.
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Proliferation of Human Peripheral Blood Mononuclear
Cells Stimulated by rSEA-EGF
This procedure was performed similar to our previous work.10
Briefly, heparinized blood was obtained from healthy donors,
and PBMCs were separated by Ficoll-Paque PLUS (GE Health-
care, Pittsburgh, Pennsylvania, USA) density gradient centri-
fugation. Freshly isolated PBMCs were suspended in Roswell
Park Memorial Institute (RPMI) 1640 culture medium and then
distributed into 96-well plates (105 cells/well) with the addition
of rSEA-EGF at various concentrations from 1 pg/mL to 1 mg/
mL. After 7 days of coculture, cell viability was detected by
MTS assay. A reference of absorbance at 630 nm served as the
blank and absorbance at 490 nm was recorded. The effect of
rSEA-EGF on cell viability was assessed as percentage of cell
viability compared with control cells, which were arbitrarily
assigned 100%. The mean value of 5 wells was calculated, and
each experiment was repeated 3 times.
Cytokine Analysis by ELISA
Freshly isolated PBMCs in 24-well plates (5  105 cells/well)
were stimulated by rSEA-EGF at 100 ng/mL. After 24 hours
cell culture, supernatants were harvested and cytokine levels
were measured by ELISA. The concentrations of IFN-g, TNF-
a, and IL-2 in cell culture supernatants were measured using
ELISA assay (Quantikine; R&D Systems, Minneapolis, Min-
nesota, USA), following the manufacturer’s instructions.
Real-Time Quantitative PCR Assay
To determine the presence of endogenous EGFR messenger
RNA (mRNA) in CNE2 or HEK 293 T cells, total RNA was
extracted and purified using an RNeasy Kit (Qiagen, Venlo,
Netherlands).Total RNA was reverse transcribed to cDNA
using PrimeScript RT Master Mix (Takara, Dalian, China).
Real-time PCR was carried out with SYBR Green Master Mix
(Applied Biosystems, Redwood, California,USA). All samples
were assayed in duplicate. Polymerase chain reaction (heating
at 95C for 10 seconds and 60C for 30 seconds) was per-
formed. The expression of target mRNA was normalized to
the expression of b-actin. Specific intron-spanning primers
were designed with the NCBI Primer-BLAST. The primers
used are: EGFR (F: 50- GCAAAGTGCCTATCAAGTG-30;
R: 50- CCAAACGGTCACCCCGTA -30) and b-actin (F: 50-
ATTGCCGACAGGATGCAGA-30; R: 50- GAGTACTTGCG-
CTCAGGAGGA -30).
RT-PCR Assay
Reverse transcription polymerase chain reaction (RT-PCR)
with 3% agarose gel electrophoresis was performed using Taq
DNA Polymerase (Takara, Dalian, China) with 1 mL cDNA as a
template per reaction. The optimized PCR conditions were as
follows: 95C 5 minutes, 95C 30 seconds, 60C 30 seconds,
72C 30 seconds for 25 cycles, 72C 10 minutes.
Western Blot Analysis
To determine the presence of endogenous EGFR, CNE2 or
HEK 293 T cells were solubilized in cell lysis solution con-
taining protease inhibitor cocktail (Roche, Branford, Connec-
ticut, USA). The protein concentration of the soluble extracts
was determined by BCA Protein Assay Kit (Thermo Fisher
Scientific, Waltham, Massachusetts, USA). Separation of
50 mg of total protein was done on 12% SDS-
polyacrylamide gels and transferred to a polyvinylidene
difluoride membrane before immunoblotting with EGFR rab-
bit antibodies and b-tubulin rabbit antibodies as indicated.
The specific proteins were detected by the enhanced chemi-
luminescence detection system (Thermo Fisher Scientific,
Waltham, Massachusetts, USA).
Tumor Cell Binding Assay
Binding of rSEA-EGF or rSEA to EGFR was detected by
ELISA as described.24 Briefly, 1  104 CNE2 or HEK 293 T
cells per well were seeded into 96-well flat-bottomed plates
overnight, then incubated with serial concentrations of rSEA-
EGF or rSEA (25, 12.5, 6.25, 3.12, 1.56, 0.78 mg/mL) at 37C
for 1 hour and then fixed with 4% neutral paraformaldehyde
(10 mmol/L Phosphate-buffered saline (PBS), 4% paraformal-
dehyde, pH 7.4) at room temperature for 1 hour. The cells were
blocked with 5 mg/mL bovine serum albumin for 2 hours. After
being washed 5 times with PBST (10 mmol/L PBS pH 7.4,
0.1% Tween-20), the cells were incubated with Strep-Tag II
mAb (1:1000) overnight, followed by horseradish peroxidase-
conjugated rabbit anti-mouse Immunoglobulin G (1:5000) and
washed as previously. Finally, the color was developed using
tetramethylbenzidine solution, and the absorbance value at 450
nm was obtained by ELISA reader.
CNE2 or HEK 293 T Cell Growth Inhibition Assay
Peripheral blood mononuclear cells (PBMCs) were incubated
with rSEA-EGF at a series of concentrations (from 10 pg/mL to
1 mg/mL) at 37C in 5% CO2 for 7 days. After 7 days of
stimulation, the PBMC and rSEA-EGF mixtures (unwashed
PBMC including supernatant, 2.5 104 cells/well) were added
to CNE2 or HEK 293 T cells (5 103 cells/well in 96-well flat-
bottomed plates) to a total volume of 200 mL. Target cells
(CNE2 or HEK 293 T cells) and effector cells (SEA pretreated
PBMCs) were cocultured at 37C in 5% CO2 for 72 hours after
which the cell supernatant and suspended cells were removed,
and fresh medium with MTS reagent was added to the remain-
ing viable cells for a 1-hour incubation. Using a microplate
reader (490 nm) to detect absorbance, the remaining viable
tumor cells were determined using the MTS assay according
to manufacturer’s instruction.
Quantification of Apoptotic and Dead Cells
Recombinant SEA-EGF-induced cell death in CNE2 cells
cocultured with PBMCs was determined by flow cytometry
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using the Annexin V-conjugated Alexa Fluor 488 (Alexa488)
Apoptosis Detection Kit (BD Pharmingen, San Diego, Califor-
nia, USA) using a procedure similar to our previous work.10
Briefly, PBMCs were pretreated with rSEA-EGF (100 ng/mL)
for 7 days and then the rSEA-EGF-treated PBMCs were cocul-
tured with CNE2 cells for 48 hours. The cells were harvested
after the addition of 0.25% trypsin-EDTA (Life Technologies,
Gibco, Frederick, Maryland, USA) immediately followed by
the addition of fetal bovine serum to terminate the reaction and
then centrifuged. The cell pellets were washed 2 times with 1
PBS, washed once with 1 binding buffer, then resuspended in
1 binding buffer, and incubated with annexin V and propi-
dium iodide (PI) for cellular staining at room temperature for
15 minutes in the dark. Cells were analyzed by flow cytometry
on a FACSCalibur instrument (BD Biosciences, San Diego,
California, USA) within 1 hour.
Statistical Analysis
GraphPad Prism software was used for statistical comparisons
with unpaired t test or 1-way analysis of variance followed by
post hoc analysis. All quantitative data were presented as mean
+ standard error of the mean. Statistical significance was con-
cluded if P value <.05.
Results
Construction of rSEA-EGF
The SEA gene of S aureus ATCC-13565 was amplified by
PCR and resulted in a 702 bp amplicon (Figure 1B). The EGF
gene was amplified by PCR and resulted in a 159 bp amplicon
(Figure 1C). The SEA-EGF fragment was amplified by splice
overlap extension PCR (Figure 1A) and resulted in an 897 bp
amplicon (Figure 1D). The entire coding region of SEA-EGF
was then cloned into a pET44a vector (Figure 2A), clones
were screened by PCR assay and NdeI and XhoI restriction
enzyme digestion, and the verifications were in accordance
with results as expected (Figure 2B and C). The candidate
positive clones were then sequenced, which showed consis-
tency with the sequences identified using the Basic Local
Alignment Search Tool program.
Expression and Identification of rSEA-EGF Protein
After sequencing confirmation of the correct reading frame of
the target protein gene in the expression vector, the recovered
plasmids were then successfully transformed into E coli strain
Rosetta-gami 2 cells. Following induction and further incuba-
tion at 37C for 6 hours, the recombinant protein was analyzed
by SDS-PAGE and found to be identical to the reported protein
Figure 1. Cloning of Staphylococcal enterotoxin A-epidermal growth factor (SEA-EGF) gene. A, Schematic presentation of splice overlap
extension polymerase chain reaction (PCR) for fused SEA-EGF. Epidermal growth factor was fused to the C-terminal of Staphylococcal
enterotoxin A (SEA) and tagged with Strep-tag II at the C-terminal. B-D, Polymerase chain reaction amplified products of SEA gene (B), EGF
gene (C), and SEA-EGF gene (D), respectively. DNA ladder is indicated on the left side, arrows indicating the PCR products, and their expected
sizes are labeled below as well.
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with a molecular weight of*34.5 kDa (Figure 3A). The SDS-
PAGE results indicated that the level of rSEA-EGF in E coli
was approximately 65% of the total bacterial protein (Figure
3A, lane 2). The expression of rSEA-EGF was confirmed using
anti-Strep-Tag II mouse mAb as the primary antibody. A spe-
cific band with an apparent molecular mass of *34.5 kDa
showed that the protein induced was of rSEA-EGF (Figure 3B).
Refolding and Purification of rSEA-EGF Protein
After the bacterial cells were lysed, rSEA-EGF remained in the
precipitate in the form of inclusion bodies. After washing 2
times, the purity of the inclusion bodies was found to be greater
than 85% (Figure 4A). The rSEA-EGF protein was refolded by
dialysis with the renaturation solution and purified by a Strep-
Tactin affinity chromatography. The target protein bound on
the gel was collected by elution and verified by SDS-PAGE
analysis. The purity of the final rSEA-EGF protein was found
to be greater than 95% (Figure 4B). After purification using
high-capacity endotoxin removal resin, the concentration of
LPS was 0.037 EU/mg as detected by the TAL method.
Liquid Chromatography-tandem Mass
Spectrometry Analysis
For successful protein identification, rSEA-EGF was processed
with tryptic digestion and subsequent LC-MS/MS analysis. The
overlap analysis showed that the coverage of digested rSEA-
EGF peptides matched with the known SEA amino acid
sequences is 88% (Figure 5A) and the coverage of digested
rSEA-EGF peptides matched with the known EGF sequences
is 47% (Figure 5B). Such high protein sequence coverage guar-
antees higher affinity and specificity for rSEA-EGF binding to
Figure 3. SDS-PAGE and immunoblot analysis of the recombinant
Staphylococcal enterotoxin A–epidermal growth factor (rSEA-EGF).
A, SDS-PAGE analysis of inducible expression of rSEA-EGF. Lanes
1 and 2: lysates of E coli cells harboring pET44a-SEA before (lane 1)
and after (lane 2) IPTG induction. Lane M: Low-molecular-weight
standard. B, Western blotting analysis of rSEA-EGF protein with anti-
Strep-Tag II antibody. Lanes 1 and 2: Lysates of Escherichia coli cells
harboring pET44a SEA-EGF before (lane 1) and after (lane 2) IPTG
induction.
Figure 4. Identification of refolded and purified recombinant Sta-
phylococcal enterotoxin A-epidermal growth factor (rSEA-EGF)
protein. A, SDS-PAGE analysis of inclusion bodies after 2 washes
with the wash buffer. Lane M: Low-molecular-weight standard; lane
1: lysates of Escherichia coli cells harboring pET44a Staphylococcal
enterotoxin A-epidermal growth factor (SEA-EGF) after IPTG
induction. Lane 2, supernatant after cell lysis; Lane 3, pellet after cell
lysis (inclusion bodies); Lane 4, supernatant after washing of inclusion
bodies; Lane 5, inclusion bodies after washing step. B, SDS-PAGE
analysis of the purified rSEA-EGF protein by Strep-Tactin affinity
chromatography.
Figure 2. Identification of the pET44a Staphylococcal enterotoxin A–epidermal growth factor (SEA-EGF) plasmid. A, Plasmid map of the
recombinant construct of pET44a-SEA-EGF. B, Identification of the pET44a-SEA-EGF by PCR assay. Lanes 1-3 are agarose gel electro-
phoresis of PCR products of different clones after using primers for PCR detection. C, Identification of the pET44a-SEA-EGF by restrictive
enzyme digestion assay with NdeI and XhoI. Lanes 1-3 are agarose gel electrophoresis of products of different clones after restrictive enzyme
digestion.
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the human EGFR-expressing carcinoma cells and subsequently
can enhance the therapeutic effects while reducing potential
damage to normal cells and tissues. The details of the identified
peptide sequences from rSEA-EGF matched with known SEA
and EGF sequences are shown in Table 1.
Recombinant SEA-EGF Induces Proliferation
of Human PBMCs
To examine the stimulating potency of rSEA-EGF on the pro-
liferation of lymphocytes, human PBMCs were incubated with
rSEA-EGF (1 pg/mL*1mg/mL) at 37C for 7 days. The data
indicated that rSEA-EGF significantly promoted human PBMC
proliferation at almost all concentrations (1 pg/mL*1 mg/mL)
tested, with the most effective dose at 100 ng/mL. Recombi-
nant SEA-EGF (1 mg/mL) increased human PBMCs prolifera-
tion from 100% to 238% when compared with vector
stimulated PBMCs (Figure 6).
Recombinant SEA-EGF Induces Cytokines Secretion
by Human PBMCs
Secretion of several key cytokines essential for antitumor or
cancer-related inflammation8-10 by rSEA-EGF-stimulated
human PBMC was also evaluated using ELISA assay. The
results indicated that IFN-g, TNF-a, and IL-2 levels were
Figure 5. Sequence identification of recombinant Staphylococcal enterotoxin A–epidermal growth factor (rSEA-EGF) using liquid chroma-
tography with mass spectrometry (LC-MS/MS) analysis. Amino acid sequence coverage of peptides digested from rSEA-EGF matched with the
known SEA (A) and EGF (B) sequences. Matching identified peptides are indicated in bold red.










SEKSEEINEKDLR SEA AAA26681.1 1-13
KKSELQGTALGNLK SEA AAA26681.1 14-27
QIYYYNEKAK SEA AAA26681.1 28-37
TENKESHDQFLQHTILFK SEA AAA26681.1 38-55
GFFTDHSWYNDLLVDFDSK SEA AAA26681.1 56-74
VDLYGAYYGYQCAGGTPNK SEA AAA26681.1 85-103
TACMYGGVTLHDNNR SEA AAA26681.1 104-118
LTEEKKVPINLWLDGK SEA AAA26681.1 119-134
KVPINLWLDGKQNTVPLETVK SEA AAA26681.1 124-144
QNTVPLETVKTNKK SEA AAA26681.1 135-148
KNVTVQELDLQAR SEA AAA26681.1 148-160




IYRDNK SEA AAA26681.1 212-217
YACNCVVGYIGERCQYR EGF AFA26280.1 29-45
CQYRDLK EGF AFA26280.1 42-48
WWELR EGF AFA26280.1 49-53
Abbreviations: EGF, epidermal growth factor; SEA, Staphylococcal
enterotoxin A.
Figure 6. Proliferation of peripheral blood mononuclear cells
(PBMCs) stimulated by different concentrations of recombinant Sta-
phylococcal enterotoxin A–epidermal growth factor (rSEA-EGF).
Cells were incubated in the presence of different concentrations of
rSEA-EGF (1 pg/mL-1 mg/mL) for 7 days at 37C in 5% CO2. MTS
reagent was added for the last 4 hours of the 7-day incubation. **P <
.01, ***P < .001, the rSEA-EGF-stimulated human PBMCs compared
with the negative control (PBS).
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significantly increased in the cell culture supernatant (Figure 7)
when PBMCs were stimulated by rSEA-EGF (100 ng/mL).
Recombinant SEA-EGF Binding Affinity to the EGFR
in CNE2 and 293 T cells
To investigate whether rSEA-EGF binds to EGFR specifically,
EGFR expression levels in CNE2 and HEK 293 T cells were
detected by quantitative PCR, RT-PCR, and Western blot anal-
ysis. Recombinant SEA-EGF binding to the CNE2 and HEK
293 T cells was analyzed using cell ELISA assay. Our real-time
quantitative PCR (Figure 8A), RT-PCR (Figure 8B), and West-
ern blot (Figure 8C) data indicated that there were high levels
of EGFR mRNA and protein expression in CNE2 cells but
much lower levels in HEK 293 T cells (Figure 8A-C). The cell
ELISA assay data showed that rSEA did not bind or only
weakly bound to both CNE2 and HEK 293 T cells (Figure
8D) and that rSEA-EGF also showed very poor binding ability
to HEK 293 T cells at all doses tested (Figure 8D, right).
However, rSEA-EGF showed expected binding ability to
CNE2 cells in a dose-dependent manner (Figure 8D, left).
Recombinant SEA-EGF Inhibited Tumor Cell Growth
In Vitro
The antitumor effect of rSEA-EGF-treated PBMCs on human
nasopharyngeal carcinoma CNE2 cells or HEK 293 T cells was
examined by MTS cell proliferation assay (Figure 9). At an
effector/target (E/T) ratio of 5:1, we found that rSEA-EGF
significantly inhibited the growth of CNE2 cells in a dose-
dependent manner (100 pg/mL-1 mg/mL), with the most effec-
tive inhibitory dose being from 100 ng/mL to 1 mg/mL. The
percentage inhibition of 1 mg/mL rSEA-EGF on CNE2 cells
was as high as 97.8% (Figure 9A). There was no effect of
rSEA-EGF on the proliferation of CNE2 cells or HEK 293 T
cells at any of the doses tested in the absence of PBMCs (Figure
9B and D). Recombinant SEA-EGF also had no effect on the
Figure 7. Cytokine secretion of peripheral blood mononuclear cells
(PBMCs) stimulated by different concentrations of recombinant Sta-
phylococcal enterotoxin A–epidermal growth factor (rSEA-EGF).
After 24 hours in culture, the supernatants were harvested and IFN-g,
TNFa, and IL-2 concentration was measured by ELISA assay. The
rSEA-EGF-stimulated human PBMCs were compared with the neg-
ative control (PBS, *P < .05, ***P < .001) PBMCs. The mean +
standard error of the mean of triplicate determinations is shown.
Figure 8. Recombinant Staphylococcal enterotoxin A–epidermal growth factor (rSEA-EGF) binds to epidermal growth factor receptor (EGFR)
in CNE2 and HEK 293 T cells. A-C, Expression of EGFR in CNE2 and HEK 293 T cell lines was detected by quantitative PCR (A), RT-PCR
assay (B), and Western blot (C). D, The binding of rSEA or rSEA-EGF fusion protein to EGFR. The binding of various concentrations of rSEA
or rSEA-EGF fusion proteins to CNE2 cancer cells or HEK 293 T cells was detected by cell ELISA assay. Values represented the mean
(standard deviation) of results from 4 samples. **P < .01, ***P < .001, compared with rSEA.
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Figure 9. Effect of recombinant Staphylococcal enterotoxin A–epidermal growth factor (rSEA-EGF) on proliferation of CNE2 and HEK 293 T
cells. A, Peripheral blood mononuclear cells (PBMCs) were treated with rSEA-EGF at different concentrations (10 pg/mL-1 mg/mL) for 7 days.
Pretreated PBMCs were then cocultured with CNE2 cells (at a density of 5  103 cells per well) in a total volume of 200 mL in 96-well flat-
bottomed plates, at 37C in 5% CO2 for 72 hours. MTS reagent was added for the last 4 hours of incubation. The mean value of 5 wells was
calculated, and each experiment was from at least 1 donor and repeated 3 times. *P< .05, *** P< .001 compared with PBMCs treated with 0 mg/
mL rSEA-EGF. B, The same procedure performed as that in Figure 9A but in the absence of PBMCs. C-D, The same procedures performed as
that in Figure 9A and 9B on HEK 293 T cells with or without the addition of PBMCs. n.s. indicates nonsignificant.
Figure 10. Effect of recombinant Staphylococcal enterotoxin A–epidermal growth factor (rSEA-EGF) on apoptosis in CNE2 cells. Peripheral
blood mononuclear cells (PBMCs) were pretreated with rSEA-EGF for 7 days, then added into CNE2 cells and cocultured for 48 hours, followed
by annexin V and PI staining and flow cytometry assay. Necrotic cells (Q1, annexin V–, PIþ), viable cells (Q4, annexin V– PI–), early (Q3,
annexin Vþ PI–), and late (Q3, annexin Vþ PIþ) apoptotic cells are defined following the instructions from the Apoptosis Detection Kit (BD
Pharmingen), and their percentages are given in the respective regions.
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proliferation of HEK 293 T cells at any dose tested when
cocultured with PBMCs (Figure 9C).
Recombinant SEA-EGF-Induced Apoptosis in CNE2 Cells
Annexin V and PI staining has been widely used to identify cell
viability and to distinguish between apoptotic and necrotic cell
death. In this study, we performed annexin V/PI double stain-
ing and measured apoptosis and necrotic cell death of CNE2
cells by flow cytometry after 48 hours coculturing with rSEA-
EGF-treated (100 ng/mL) PBMCs. We found that when CNE2
cells were cocultured with rSEA-EGF-treated PBMCs, only
0.71% of the total cells were detected in the necrotic cell region
(Q1, annexin V, PIþ), but 72.6% of the total cells were apop-
totic cells (Q2 þ Q3, annexin Vþ), with 60.4% of them under-
going early (Q3, annexin Vþ, PI) and 12.2% of them
undergoing late (Q2, annexin Vþ, PIþ) apoptosis (Figure 10).
Nonetheless, rSEA-EGF-treated PBMCs markedly increased
the percentage of early and late apoptotic cells. Coculture of
CNE2 cells with untreated PBMCs also increased the percent-
age of apoptotic CNE2 cells but with much less potency than if
PBMCs were pretreated with rSEA-EGF (Figure 10).
Discussion
In humans, the number of natural tumor-reactive T cells is
often low. Preclinical and clinical studies have shown that
stimulation of T cells by immunogenic proteins has an ability
to interfere with established growing cancer.25 In the tumor-
targeted superantigen concept, bacterial superantigens, the
most potent known activators of human T cells, are used to
activate and recruit large numbers of T cells to the targeted
tumors.8-10 Cancer immunotherapy through a tumor cell–spe-
cific small-molecule ligand, or LTTs, has been arousing enthu-
siasm for many reasons, that is, LTTs were believed to be
easily accessible, less expensive, less antigenic than mAbs,
and, more importantly, easily enhance the ability of drugs get-
ting into solid tumors but decreasing drug delivery to normal
cells.26-28 In fact, LTTs could not only be used as a specific
delivery system for cancer immunotherapy but also represent a
novel concept for the delivery of immune agents for many other
diseases, such as food poisoning,8,28,29 skin inflammation,30
toxic shock syndrome, autoimmune diseases,28, and so on.
Therefore, in this study, we constructed, expressed, and char-
acterized a novel recombinant SEA-EGF and demonstrated
that purified rSEA-EGF could stimulate the proliferation of
human PBMCs, thereby releasing cytokines such as IFN-g,
TNF-a, IL-2 and significantly inhibiting the proliferation of
CNE2 cells, at least via promoting their apoptosis. To our
knowledge, this is the first study to report using a superantigen
chimeric protein against nasopharyngeal cancer.
Challenges in LTTs require high delivery specificity and
minimum potential damage to healthy cells,31 which we care-
fully considered in our work. By splice overlap extension
PCR22, we successfully combined SEA with EGF while retain-
ing EGF binding ability. In our pilot assay, the purified chimeric
protein rSEA-EGF had excellent binding affinity when incu-
batedwith theCNE2 tumor cell line, had high stimulatory ability
on PBMCs, and had ideal antitumor effects. Similar work has
been accomplished by Yousefi et al,28,32 using a mature form of
SEA and different lead sequence. As seen in our present work,
the purified rSEA-EGF significantly elicited the secretion of
tumoricidal or cancer-related inflammatory cytokines (IFN-g,
TNF-a, and IL-2) by PBMCs, which is an ideal indicators for the
chimeric protein. Thus, this work is a good foundation for our
future chimeric protein engineering research and also a possible
direction for all targeted immunotoxin research.
Multiple cytokines and chemokines can be generated in
different tissues as a response of the body to cancer, however,
whether the cytokines and chemokines induced by rSEA-EGF
can interact together through a form of cross-talk and affect
immunotherapy responses has not been well characterized.8-10
Recently, we found that when cocultured with PBMCs, SEA
induced crosstalk-dependent activation of extracellular regu-
lated protein kinases and signal transducers and activators of
transcription and the production of tumor-suppressive cyto-
kines.10 We plan to use our rSEA-EGF fusion protein and
coculture with PBMCs to investigate chemokine and chemo-
kine receptor network-related therapeutic interventions with
cancer cells, which may yield important information for under-
standing the immune-related mechanisms of cancer develop-
ment that could subsequently lead to applications in cancer
immunotherapy.
Conclusion
Our work introduces a new superantigen, rSEA-EGF fusion
protein, for targeted treatment of EGFR-expressing cancer
(ie, nasopharyngeal cancer) cells. It could be of great benefit
to further explore with intensive studies its actual antitumor
effects on animals and the molecular mechanisms involved.
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